The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Open accessAbstract
BACKGROUND: Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety. METHODS: Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle). The primary end point was overall survival. RESULTS: A total of 573 patients from 85 centers underwent randomization. The median age was 56 years, and 84 percent of patients had undergone debulking surgery. At a median follow-up of 28 months, the median survival was 14.6 months with radiotherapy plus temozolomide and 12.1 months with radiotherapy alone. The unadjusted hazard ratio for death in the radiotherapy-plus-temozolomide group was 0.63 (95 percent confidence interval, 0.52 to 0.75; P<0.001 by the log-rank test). The two-year survival rate was 26.5 percent with radiotherapy plus temozolomide and 10.4 percent with radiotherapy alone. Concomitant treatment with radiotherapy plus temozolomide resulted in grade 3 or 4 hematologic toxic effects in 7 percent of patients. CONCLUSIONS: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The standard treatment for high-grade gliomas such as glioblastoma (grade IV) is surgery followed by chemotherapy and radiation therapy [45].”
From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“Since the current clinically actionable sub-compartments are TC (i.e., considered for surgery) and WT (i.e., considered for radiotherapy)42, performance improvements of their boundary detection may contribute to the model’s clinical impact and relevance.”
From Federated learning enables big data for rare cancer boundary detection (2022) · cites this paper as [42]
In the citing paper
“Stupp et al. originally reported that treatment of patients with GBM with TMZ and radiation resulted in an approximately 20% increase in progression-free survival compared with radiation therapy alone.39”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [39]
In the citing paper
“An effect size of 20% increase in survival was considered to be biologically significant when comparing survival in TMZ versus combination T/N-treated mice.39”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [39]
In the citing paper
“An increase of median survival of 13.4 months for patients treated with a combination of MFH and radiotherapy after glioblastoma recurrence was obtained (Figure 7E). As compared to the abovementioned historical control group, where the median survival after recurrence was 6.2 months, this increase is substantial.”
From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [223]
In the citing paper
“An increase of median survival of 13.4 months for patients treated with a combination of MFH and radiotherapy after glioblastoma recurrence was obtained (Figure 7E). As compared to the abovementioned historical control group, where the median survival after recurrence was 6.2 months, this increase is substantial.”
From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [224]
In the citing paper
“It is highly unlikely that this additional technical support would translate into a 3-month prolongation of median survival, which is in the range of the benefit seen with the introduction of TMZ.26”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [26]
In the citing paper
“However, a strong selection bias and inclusion of patients with pseudoprogression after initial TMZ chemoradiotherapy cannot be ruled out in this uncontrolled routine practice patient population.26”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [26]
In the citing paper
“In the PriDE dataset reflecting routine clinical use of the device, patients who received TTFields at first recurrence were treated for a median of 6.2 months and had a median survival of 20 months, comparing favorably with recent trial results investigating other novel agents.”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [26]
In the citing paper
“while the published Temozolomide data indicates an increase of about 20% in OS compared to ionizing radiation treatment alone [14]”
From Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields) (2009) · cites this paper as [14]
In the citing paper
“However, if we assume that the TTFields therapeutic efficacy for newly diagnosed patients is similar to recurrent GBM, i.e. the median of OS is increased by 270% [1] while the published Temozolomide data indicates an increase of about 20% in OS compared to ionizing radiation treatment alone [14], the results presented in Figure 6 point towards additivity between TTFields and Temozolomide.”
From Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields) (2009) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Self-citationPocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., García‐Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,256
Walker, M. D., Alexander, E., Hunt, W., Maccarty, C. S., Mahaley, M., Mealey, J., Norrell, H., Owens, G., Ransohoff, J., Wilson, C. B., et al. (1978) · Journal of Neurosurgery · doi:10.3171/jns.1978.49.3.0333 · Cited by 1,751
Walker, M. D., Green, S. B., Byar, D., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W., Maccarty, C. S., Mahaley, M., Mealey, J., et al. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012043032303 · Cited by 1,727
DeAngelis, L. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101113440207 · Cited by 1,689
Pathology and genetics of tumours of the nervous system.
Kleihues, P., & Cavennee, W. (2000) · International Agency for Research on Cancer eBooks · Cited by 1,432
Westphal, M., Hilt, D. C., Bortey, E. B., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J. E., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,374
Curran, W. J., Scott, C., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C., Rotman, M., Asbell, S., Krisch, R. E., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.9.704 · Cited by 1,309
Flagged first, then by citations
Research works printed but not linked: 5
- Green SB, 1983, Cancer Treat Rep, 67, 121
- Brock CS, 1998, Cancer Res, 58, 4363
- 10.1200/JCO.20.5.1375 · DOI
- Shapiro WR, 1992, Rev Neurol, 148, 428
- Wick W, 2002, Cancer Res, 62, 1915
Cited by
Sorted by citations
Items 901–1,000 of 1,070
Mazor, G., Levin, L., Picard, D. J., Ahmadov, U., Carén, H., Borkhardt, A., Reifenberger, G., Leprivier, G., Remke, M., & Rotblat, B. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1477-5 · Cited by 175
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series
Dresemann, G. P. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi317 · Cited by 173
Diagnosis and Treatment of Recurrent High-Grade Astrocytoma
Butowski, N. A., Sneed, P. K., & Chang, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7522 · Cited by 172
Fadul, C. E., Fisher, J. L., Hampton, T. H., Lallana, E. C., Li, Z., Gui, J., Szczepiorkowski, Z. M., Tosteson, T. D., Rhodes, C. H., Wishart, H. A., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318215e300 · Cited by 172
High-Resolution Mechanical Imaging of Glioblastoma by Multifrequency Magnetic Resonance Elastography
Streitberger, K., Reiss-Zimmermann, M., Freimann, F. B., Bayerl, S., Guo, J., Arlt, F., Wuerfel, J. T., Braun, J., Hoffmann, K., & Sack, I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110588 · Cited by 172
Robinson, M. W., Overmeyer, J. H., Young, A. M., Erhardt, P., & Maltese, W. A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201006x · Cited by 172
Russo, A. L., Kwon, H., Burgan, W. E., Carter, D., Beam, K., Xu, W., Zhang, J., Slusher, B. S., Chakravarti, A., Tofilon, P. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2079 · Cited by 172
Agnihotri, S., Gajadhar, A. S., Ternamian, C., Gorlia, T., Alfaro-Munoz, K. D., Mischel, P. S., Kelly, J. R., McGown, G., Thorncroft, M. R., Carlson, B. L., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci59334 · Cited by 176
Self-citationAldave, G., Tejada, S., Pay, E., Marigil, M., Bejarano, B., Idoate, M. A., & Díez-Valle, R. (2013) · Neurosurgery · doi:10.1227/neu.0b013e31828c3974 · Cited by 173
Wang, S., Hong, J., Hsueh, C., & Chiang, C. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.128 · Cited by 172
Würth, R., Bajetto, A., Harrison, J. K., Barbieri, F., & Florio, T. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00144 · Cited by 172
Overmeyer, J. H., Young, A. M., Bhanot, H., & Maltese, W. A. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-69 · Cited by 174
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., & Bigner, D. D. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.04.001 · Cited by 173
Halatsch, M., Schmidt, U. I., Behnke‐Mursch, J., Unterberg, A. W., & Wirtz, C. R. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.01.003 · Cited by 172
Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic
Schomas, D. A., Laack, N. N. I., Rao, R. D., Meyer, F. B., Shaw, E. G., O’Neill, B. P., Giannini, C., & Brown, P. D. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-102 · Cited by 171
Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging
Clarke, J. L., & Chang, S. M. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0035-4 · Cited by 171
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
Thon, N., Kreth, S., & Kreth, F. W. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s50208 · Cited by 180
del Alcazar, C. R. G., Hardebeck, M. C., Mukherjee, B., Tomimatsu, N., Gao, X., Yan, J., Xie, X., Bachoo, R. M., Li, L., Habib, A. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1607 · Cited by 172
Galldiks, N., Langen, K., & Pope, W. B. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov118 · Cited by 171
Gittleman, H. R., Lim, D., Kattan, M. W., Chakravarti, A., Gilbert, M. R., Lassman, A. B., Lo, S. S.-M., Machtay, M. X., Sloan, A. E., Sulman, E. P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now208 · Cited by 173
Kamran, N., Kadiyala, P., Saxena, M., Candolfi, M., Li, Y., Moreno-Ayala, M. A., Raja, N. S., Shah, D., Lowenstein, P. R., & Castro, M. G. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.003 · Cited by 178
Pinto, G., Sáenz‐de‐Santa‐María, I., Chastagner, P., Perthame, É., Delmas, C., Toulas, C., Moyal, E. C., Brou, C., & Zurzolo, C. (2020) · Biochemical Journal · doi:10.1042/bcj20200710 · Cited by 181
Convection-enhanced delivery for the treatment of brain tumors
Debinski, W., & Tatter, S. B. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.99 · Cited by 170
Prognosis and Treatment of Spinal Cord Astrocytoma
Minehan, K. J., Brown, P. D., Scheithauer, B. W., Krauss, W. E., & Wright, M. P. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.04.060 · Cited by 170
Patterns and Timing of Recurrence After Temozolomide-Based Chemoradiation for Glioblastoma
Milano, M. T., Okunieff, P. G., Donatello, R. S., Mohile, N. A., Sul, J., Walter, K. A., & Korones, D. N. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.09.018 · Cited by 170
Kim, H., Moon, J. Y., Ahn, K. S., & Cho, S. K. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/596496 · Cited by 175
Grossman, S. A., Ye, X., Chamberlain, M. C., Mikkelsen, T., Batchelor, T. T., Desideri, S., Piantadosi, S., Fisher, J. D., & Fine, H. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6895 · Cited by 170
De novo Induction of Genetically Engineered Brain Tumors in Mice Using Plasmid DNA
Wiesner, S. M., Decker, S. A., Larson, J. D., Ericson, K., Forster, C. L., Gallardo, J. L., Long, C., Demorest, Z. L., Zamora, E. A., Low, W. C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1800 · Cited by 170
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma
Cosset, E. C., Ilmjärv, S., Dutoit, V., Elliott, K. C., Schalscha, T. V., Camargo, M. F., Reiss, A., Moroishi, T., Seguin, L., Gomez, G. G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.016 · Cited by 172
Cloughesy, T. F., Landolfi, J. C., Vogelbaum, M. A., Ostertag, D. G., Elder, J. B., Bloomfield, S. M., Carter, B. S., Chen, C. C., Kalkanis, S. N., Kesari, S., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy075 · Cited by 170
Perrin, S. L., Samuel, M. S., Koszyca, B., Brown, M. P., Ebert, L. M., Oksdath, M., & Gomez, G. A. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180444 · Cited by 175
Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling
Zhang, X., Yang, K., Chen, C., He, Z., Wang, Q., Feng, H., Lv, S., Wang, Y., Mao, M., Liu, Q., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00528-3 · Cited by 173
Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
Himes, B. T., Geiger, P. A., Ayasoufi, K., Bhargav, A. G., Brown, D. A., & Parney, I. F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.770561 · Cited by 180
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovičová, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 175
The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y. (2021) · Cells · doi:10.3390/cells10030484 · Cited by 169
Glioblastoma multiforme: a review of therapeutic targets
Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Bortoff, K., Bigner, D. D., Yan, H., & Adamson, D. C. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902942348 · Cited by 174
Silver nanoparticles: a novel radiation sensitizer for glioma?
Liu, P., Huang, Z., Chen, Z., Xu, R., Wu, H., Zang, F., Wang, C., & Gu, N. (2013) · Nanoscale · doi:10.1039/c3nr01351k · Cited by 169
Galldiks, N., Rapp, M., Stoffels, G., Fink, G. R., Shah, N. J., Coenen, H. H., Sabel, M., & Langen, K. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2251-4 · Cited by 169
Scholz, A., Harter, P. N., Cremer, S., Yalcin, B. H., Gurnik, S., Yamaji, M., Tacchio, M. D., Sommer, K., Baumgarten, P., Bähr, O., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505505 · Cited by 171
Radioresistance in Glioblastoma and the Development of Radiosensitizers
Ali, M. Y., Oliva, C. R., Noman, A. S. M., Allen, B. G., Goswami, P. C., Zakharia, Y., Monga, V., Spitz, D. R., Buatti, J. M., & Griguer, C. E. (2020) · Cancers · doi:10.3390/cancers12092511 · Cited by 183
Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
Navarro, A. G., Björklund, A. T., & Chekenya, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00202 · Cited by 174
Widhalm, G., Kiesel, B., Wöehrer, A., Traub‐Weidinger, T., Preusser, M., Marosi, C., Prayer, D., Hainfellner, J. A., Knosp, E., & Wolfsberger, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076988 · Cited by 169
Self-citationBrain Tumor Stem Cells: Bringing Order to the Chaos of Brain Cancer
Dirks, P. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.6792 · Cited by 170
Is fluorescein-guided technique able to help in resection of high-grade gliomas?
Acerbi, F., Broggi, M. A., Eoli, M., Anghileri, E., Cavallo, C., Boffano, C., Cordella, R., Cuppini, L., Pollo, B., Schiariti, M. P., et al. (2014) · Neurosurgical FOCUS · doi:10.3171/2013.11.focus13487 · Cited by 173
Hutterer, M., Nowosielski, M., Putzer, D., Waitz, D., Tinkhauser, G., Kostron, H., Muigg, A., Virgolini, I. J., Staffen, W., Trinka, E., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.086645 · Cited by 168
Brynolfsson, P., Nilsson, D., Torheim, T., Asklund, T., Karlsson, C. T., Trygg, J., Nyholm, T., & Garpebring, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-04151-4 · Cited by 168
Zhu, Z., Zhang, H., Chen, B., Liu, X., Zhang, S., Zong, Z., & Gao, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.588552 · Cited by 173
Li, Z., Meng, X., Wu, P., Zha, C., Han, B., Li, L., Sun, N., Qi, T., Qin, J., Zhang, Y., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0258 · Cited by 168
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
Ahluwalia, M. S., Reardon, D. A., Abad, A. P., Curry, W. T., Wong, E. T., Figel, S. A., Mechtler, L. L., Peereboom, D. M., Hutson, A. D., Withers, H. G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00996 · Cited by 168
Emerging Therapies for Glioblastoma
Thomas, A. A., Brennan, C., DeAngelis, L. M., & Omuro, A. M. P. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1701 · Cited by 173
miR-182 as a Prognostic Marker for Glioma Progression and Patient Survival
Jiang, L., Mao, P., Song, L., Wu, J., Huang, J., Lin, C., Yuan, J. X., Qu, L., Cheng, S., & Li, J. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090812 · Cited by 167
Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines
Fu, J., Shao, C.-J., Chen, F.-R., Ng, H., & Chen, Z. (2009) · Neuro-Oncology · doi:10.1093/neuonc/nop005 · Cited by 167
MicroRNA in Glioblastoma: An Overview
Banelli, B., Forlani, A., Allemanni, G., Morabito, A., Pistillo, M. P., & Romani, M. (2017) · International Journal of Genomics · doi:10.1155/2017/7639084 · Cited by 171
Lipková, J., Angelikopoulos, P., Wu, S., Alberts, E., Wiestler, B., Diehl, C., Preibisch, C., Pyka, T., Combs, S. E., Hadjidoukas, P. E., et al. (2019) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2019.2902044 · Cited by 167
Applications of radiomics and machine learning for radiotherapy of malignant brain tumors
Köcher, M., Ruge, M. I., Galldiks, N., & Lohmann, P. (2020) · Strahlentherapie und Onkologie · doi:10.1007/s00066-020-01626-8 · Cited by 171
A Review of Newly Diagnosed Glioblastoma
Oronsky, B. T., Reid, T. R., Oronsky, A. L., Sandhu, N., & Knox, S. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.574012 · Cited by 177
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement
Bagley, S. J., Kothari, S., Rahman, R. M., Lee, E. Q., Dunn, G. P., Galanis, E., Chang, S. M., Nabors, B., Ahluwalia, M. S., Stupp, R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2750 · Cited by 177
Self-citationMiller, G. E., Murphy, M. L. M., Cashman, R., Ma, R., Ma, J., Arevalo, J. M. G., Kobor, M. S., & Cole, S. W. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.05.016 · Cited by 166
Cho, D., Yang, W.-K., Lee, H.-C., Hsu, D.-M., Lin, H., Lin, S., Chen, C., Harn, H., Liu, C.-L., Lee, W.-Y., et al. (2011) · World Neurosurgery · doi:10.1016/j.wneu.2011.08.020 · Cited by 166
Newcomb, E. W., Demaria, S., Lukyanov, Y., Shao, Y., Schnee, T., Kawashima, N., Lan, L., DeWyngaert, J. K., Zagzag, D., McBride, W. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0593 · Cited by 166
Pessina, F., Navarria, P., Cozzi, L., Ascolese, A. M., Simonelli, M., Santoro, A., Clerici, E., Rossi, M., Scorsetti, M., & Bello, L. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2559-9 · Cited by 166
Binder, Z. A., Thorne, A. H., Bakas, S., Wileyto, E. P., Bilello, M., Akbari, H., Rathore, S., Ha, S. M., Zhang, L., Ferguson, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.006 · Cited by 166
Self-citationHerrlinger, U., Rieger, J., Koch, D., Loeser, S., Blaschke, B., Kortmann, R., Steinbach, J. P., Hundsberger, T., Wick, W., Meyermann, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9104 · Cited by 166
Self-citationChronotherapy and the molecular clock: Clinical implications in oncology☆
Innominato, P. F., Lévi, F., & Bjarnason, G. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.06.002 · Cited by 168
Chu, H. H., Choi, S. H., Ryoo, I., Kim, S. C., Yeom, J. A., Shin, H., Jung, S. C., Lee, A. L., Yoon, T. J., Kim, T. M., et al. (2013) · Radiology · doi:10.1148/radiol.13122024 · Cited by 166
Yi, G., Huang, G., Guo, M., Zhang, X., Wang, H., Deng, S., Li, Y., Xiang, W., Chen, Z., Pan, J., et al. (2019) · Brain · doi:10.1093/brain/awz202 · Cited by 167
Walbert, T., Harrison, R. A., Schiff, D., Avila, E. K., Chen, M., Kandula, P., Lee, J. W., Rhun, É. L., Stevens, G. H. J., Vogelbaum, M. A., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab152 · Cited by 165
Self-citationThe use of cannabinoids as anticancer agents
Velasco, G., Hernández‐Tiedra, S., Dávila, D., & Lorente, M. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.05.010 · Cited by 168
When Gross Total Resection of a Glioblastoma Is Possible, How Much Resection Should Be Achieved?
Chaichana, K. L., Cabrera‐Aldana, E. E., Jusué-Torres, I., Wijesekera, O., Olivi, A., Rahman, M., & Quiñones‐Hinojosa, A. (2014) · World Neurosurgery · doi:10.1016/j.wneu.2014.01.019 · Cited by 164
Henriksson, R., Asklund, T., & Poulsen, H. S. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0565-x · Cited by 164
Oliva, C. R., Moellering, D. R., Gillespie, G. Y., & Griguer, C. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024665 · Cited by 164
Akbari, H., Macyszyn, L. J., Da, X., Bilello, M., Wolf, R. L., Martinez‐Lage, M., Biros, G., Alonso‐Basanta, M., O’Rourke, D. M., & Davatzikos, C. A. (2016) · Neurosurgery · doi:10.1227/neu.0000000000001202 · Cited by 164
Cheng, P., Wang, J., Waghmare, I., Sartini, S., Coviello, V., Zhang, Z., Kim, S.-H., Mohyeldin, A., Pavlyukov, M. S., Minata, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2860 · Cited by 168
Health related quality of life outcomes in cancer clinical trials
Bottomley, A., Flechtner, H., Efficace, F., Vanvoorden, V., Coens, C., Therasse, P., Velikova, G., Blazeby, J. M., & Greimel, E. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.05.007 · Cited by 164
Yang, C. H., Yue, J., Pfeffer, S. R., Fan, M., Paulus, E., Hosni-Ahmed, A., Sims, M., Qayyum, S., Davidoff, A. M., Handorf, C. R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.593863 · Cited by 164
Inhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization
Camphausen, K., & Tofilon, P. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6202 · Cited by 162
Anti-angiogenic therapy for high-grade glioma
Ameratunga, M., Pavlakis, N., Wheeler, H., Grant, R., Simes, J. R., & Khasraw, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008218.pub4 · Cited by 168
Rocha, C. R. R., Garcia, C. C. M., Vieira, D. B., Quinet, A., de Andrade-Lima, L. C., Munford, V., Belizário, J. E., & Menck, C. F. M. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.465 · Cited by 163
Ardon, H., Gool, S. W. V., Verschuere, T., Maes, W., Fieuws, S., Sciot, R., Wilms, G., Demaerel, P., Goffin, J., Calenbergh, F. V., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1261-1 · Cited by 163
Infrared thermal imaging: A review of the literature and case report
Kateb, B., Yamamoto, V. N., Yu, C., Grundfest, W. S., & Gruen, J. P. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.03.043 · Cited by 163
New (alternative) temozolomide regimens for the treatment of glioma
Wick, W., Platten, M., & Weller, M. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-078 · Cited by 163
Self-citationGaspar, N., Marshall, L. V., Perryman, L., Bax, D. A., Little, S. E., Viana‐Pereira, M., Sharp, S. Y., Vassal, G., Pearson, A. D. J., Reis, R. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1250 · Cited by 167
Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide
Murphy, S. F., Varghese, R. T., Lamouille, S., Guo, S., Pridham, K. J., Kanabur, P., Osimani, A. M., Sharma, S., Jourdan, J., Rodgers, C. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1286 · Cited by 163
Chaichana, K. L., McGirt, M. J., Frazier, J., Attenello, F. J., Guerrero‐Cazares, H., & Quiñones‐Hinojosa, A. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9609-2 · Cited by 163
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
Yang, P., Zhang, W., Wang, Y., Peng, X., Chen, B., Qiu, X., Li, G., Li, S., Wu, C., Yao, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5683 · Cited by 170
Cui, X., Ma, C., Vasudevaraja, V., Serrano, J., Tong, J., Peng, Y., DeLorenzo, M., Shen, G., Frenster, J. D., Morales, R. T., et al. (2020) · eLife · doi:10.7554/elife.52253 · Cited by 163
on behalf of the GWCA1208 study group, Twelves, C. J., Sabel, M., Checketts, D., Miller, S., Tayo, B., Jové, M., Brazil, L., & Short, S. C. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01259-3 · Cited by 163
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
Kuter, D. J. (2022) · Haematologica · doi:10.3324/haematol.2021.279512 · Cited by 164
Gahramanov, S., Muldoon, L. L., Varallyay, C. G., Li, X., Kraemer, D. F., Fu, R., Hamilton, B. E., Rooney, W. D., & Neuwelt, E. A. (2013) · Radiology · doi:10.1148/radiol.12111472 · Cited by 162
Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma
Beig, N., Patel, J., Prasanna, P., Hill, V., Gupta, A., Correa, R., Bera, K., Singh, S., Partovi, S., Varadan, V., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18310-0 · Cited by 157
Racial, ethnic and socioeconomic disparities in the treatment of brain tumors
Curry, W. T., & Barker, F. G. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9840-5 · Cited by 152
The aryl hydrocarbon receptor and the gut–brain axis
Barroso, A., Mahler, J. V., Fonseca-Castro, P. H., & Quintana, F. J. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00585-5 · Cited by 152
Kitange, G. J., Mladek, A. C., Carlson, B. L., Schroeder, M. A., Pokorny, J. L., Cen, L., Decker, P. A., Wu, W., Lomberk, G. A., Gupta, S. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0560 · Cited by 151
Dasari, V. R., Kaur, K., Velpula, K. K., Gujrati, M., Fassett, D., Klopfenstein, J. D., Dinh, D. H., & Rao, J. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010350 · Cited by 151
RetractedMa, W., Wang, Y., Zhang, R., Yang, F., Zhang, D., Huang, M., Zhang, L., Dorsey, J. F., Binder, Z. A., O’Rourke, D. M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00147-8 · Cited by 143
Rais, R., Jančařík, A., Tenora, L., Nedelcovych, M., Alt, J., Englert, J., Rojas, C., Le, A., Elgogary, A., Tan, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01069 · Cited by 138
Tumor treating fields increases membrane permeability in glioblastoma cells
Chang, E., Patel, C. B., Pohling, C., Young, C., Song, J., Flores, T. A., Zeng, Y., Joubert, L.-M., Arami, H., Natarajan, A., et al. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0130-x · Cited by 137
Chudnovsky, Y., Kim, D., Zheng, S., Whyte, W. A., Bansal, M., Bray, M.-A., Gopal, S., Theisen, M. A., Bilodeau, S., Thiru, P., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.032 · Cited by 136
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma
Banelli, B., Carra, E., Barbieri, F., Würth, R., Parodi, F., Pattarozzi, A., Carosio, R., Forlani, A., Allemanni, G., Marubbi, D., et al. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1090063 · Cited by 135
Predicting the electric field distribution in the brain for the treatment of glioblastoma
Miranda, P. C., Mekonnen, A., Salvador, R., & Basser, P. J. (2014) · Physics in Medicine and Biology · doi:10.1088/0031-9155/59/15/4137 · Cited by 131
Metadata
- Authors
- Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., & Mirimanoff, R. O.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- Princess Margaret Cancer Centre (CA)
- University of Tübingen (DE)
- Western University (CA)
- University Medical Center Utrecht (NL)
- Azienda Ospedale - Università Padova (IT)
- Medical University of Vienna (AT)
- University Hospital Regensburg (DE)
- University Hospital of Bern (CH)
- Queen's University (CA)
- European Organisation for Research and Treatment of Cancer (NL)
- University of Calgary (CA)
- Canadian Cancer Trials Group (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-10
- Volume
- 352
- Issue
- 10
- Pages
- 987-996
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096287682
- Cited by
- 21,807
- References
- 35
- Citations by year
- 2026: 1259 · 2025: 1369 · 2024: 1444 · 2023: 1500 · 2022: 1532 · 2021: 1614 · 2020: 1453 · 2019: 1256 · 2018: 1167 · 2017: 1156 · 2016: 1068 · 2015: 1110 · 2014: 1019 · 2013: 901 · 2012: 872
- FWCI
- 171.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- CRC Press eBooks (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion, other-oa)
- Funders
- National Cancer Institute (5U10-CA11488-30, 5U10-CA11488-32, 5U10-CA11488-33, 5U10-CA11488-31, U10CA011488, 5U10 CA11488-34)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
- Keywords
- glioblastoma, temozolomide, radiotherapy, concurrent chemoradiotherapy, adjuvant chemotherapy, overall survival, hematologic toxicity, newly diagnosed brain tumors
- MeSH terms
- Temozolomide, Adrenal Cortex Hormones, Adult, Aged, Brain Neoplasms, Dacarbazine, Female, Glioblastoma, Humans, Male, Middle Aged, Radiotherapy, Computer-Assisted, Proportional Hazards Models, Survival Analysis, Chemotherapy, Adjuvant, Disease Progression, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
